Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
IPI Legacy Liquidation Co (IPI Legacy Liquidation), formerly Impel Pharmaceuticals Inc, is a clinical-stage biotechnology company that develops and commercializes transformative therapies for patients suffering from diseases with high unmet medical needs. Its product includes Trudhesa, a dihydroergotamine mesylate nasal spray approved for the acute treatment of migraine in adults. It utilizes Precision Olfactory Delivery (POD) technology to develop drugs. IPI Legacy Liquidation products are primarily used by patients suffering from migraines. IPI Legacy Liquidation is headquartered in Seattle, Washington, the US.
IPI Legacy Liquidation Co premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Trudhesa | Trudhesa |
| Platform: | |
| Precision Olfactory Delivery (POD) Technology |
Competitor Comparison
| Key Parameters | IPI Legacy Liquidation Co | OptiNose Inc | AIM ImmunoTech Inc | Ainos Inc | Royer Biomedical Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Seattle | Yardley | Ocala | Houston | Frederick |
| State/Province | Washington | Pennsylvania | Florida | Texas | Maryland |
| No. of Employees | 160 | 127 | 21 | 44 | - |
| Entity Type | Private | Private | Public | Public | Private |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Leonard S. Paolillo | President - Interim; Chief Executive Officer | Senior Management | - | - |
| John Hoekman | Chief Technology and Development Officer | Senior Management | - | - |
| Rigo Canal | Vice President - Commercial Operations and Analytics | Senior Management | - | - |
| Sarah Wille | Vice President - Human Resources | Senior Management | - | - |
| Scott Youmans | Senior Vice President - Technical Operations | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer